Wedbush analyst Liana Moussatos reiterated a Hold rating on Omeros (NASDAQ:OMER) Corp on Tuesday, setting a price target of $18, which is approximately 7.26% below the present share price of $19.41.
Moussatos expects Omeros Corp to post earnings per share (EPS) of -$0.66 for the first quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Moderate Buy rating of shares in Omeros, with an average price target of $25.5.
The analysts price targets range from a high of $34 to a low of $18.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $26.11 million and a net profit of -$25.43 million. The company's market cap is $1.23 billion.
According to TipRanks.com, Wedbush analyst Liana Moussatos is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.8% and a 56.75% success rate.
Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.